Sara Robinson, senior associate healthcare architect at McMillan Pazdan Smith Architecture, and Jamie Feinour, vice president ...

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

Cryotherapy is emerging as a promising strategy to prevent chemotherapy-induced peripheral neuropathy, but adoption in clinical practice remains limited.

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...